



THOMSON REUTERS

NEWS RELEASE

FOR IMMEDIATE RELEASE

AUSTRALIA'S MEDICAL RESEARCH COMMERCIALISATION FUND CHOOSES *THOMSON PHARMA*® FROM THOMSON REUTERS

Melbourne, AUSTRALIA, August 24, 2010 – Thomson Reuters today announces that the Medical Research Commercialisation Fund (MRCF) has chosen *Thomson Pharma*® to serve the key commercialisation and business development needs of its 27 members.

The MRCF is an innovative investment collaboration, that invests in the most promising opportunities emanating from its members, including 27 of Australia's leading Medical Research Institutes and associated research hospitals from Victoria, New South Wales, Western Australia and Queensland. *Thomson Pharma*, the largest and most comprehensive database of critical pharmaceutical market intelligence, is widely used by clinical researchers, competitive intelligence analysts, business development professionals and brand management employees, globally.

MRCF has facilitated individual subscriptions to *Thomson Pharma* for its member organisations, providing them with access to critical pipeline and competitor knowledge to help them optimise their product portfolio, monitor industry developments and make informed investment decisions. Members of MRCF can find relevant data integrated from more than 40 pharmaceutical data sources placed in context with unique abstracts, commentaries and analysis prepared by Thomson Reuters industry experts.

Said Dr. Chris Nave, Principal Executive of MRCF, "We believe that *Thomson Pharma* is one of the leading information databases for early stage biomedical development and commercialisation data, and we are delighted to be able to provide our members with access to this valuable tool."

"Reliable preclinical intelligence is particularly important for informing both our research and commercialisation activities" said Dr. Julian Clark, Head of Business Development at the Walter and Eliza Hall Institute. "*Thomson Pharma* provides us with a unique depth and scale of information at this early stage of discovery and translation, particularly for intelligence not easily accessible in the public domain."

"*Thomson Pharma* is an integral tool for assessing new discoveries derived from the Institute for Molecular Bioscience," said Dr. Peter Isdale, CEO, IMBcom Pty Ltd. "Rather than being reactive and waiting for commercial opportunities, this intelligence enables us to forecast and shape the direction of our biotechnology development pathways."

"We are pleased to be seen as a trusted Life Sciences intelligence provider by some of Australia's top medical research institutes whose collaboration interests are represented by MRCF, a highly respected investment and commercialisation body in Australia," said Jeroen Prinsen, Senior Director of Australia & New Zealand, Healthcare & Science business of Thomson Reuters. "Australia has extensive research in drug discovery and development, and requires the best pharmaceutical content and competitive intelligence available to meet the sector's commercialisation and business expansion needs."

Thomson Pharma covers the entire competitor intelligence needs of pharmaceutical innovators — the latest drugs, compounds, genetic sequences and targets, clinical trials and licensing opportunities, patents, journals, conferences, academic articles and more.



THOMSON REUTERS

Page 2 of 2

For more information about *Thomson Pharma*, please visit www.thomson-pharma.com

The Medical Research Commercialisation Fund (MRCF)

The MRCF provides dedicated, investment funding for the commercialisation of early-stage research discoveries emanating from its member institutes and their affiliated hospitals. The collaborative nature of the MRCF provides a supportive investment process, fostering best practices in commercialisation and encouraging innovation. Our member base with exclusive access to funding is comprised of many of Victoria, New South Wales, Western Australia and Queensland's leading Medical Research Institutes and their affiliated research hospitals. The MRCF is an evergreen fund that is managed by [Brandon Capital Partners](#), an experienced life science fund manager. Visit: <http://www.mrcf.com.au/>

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.

MEDIA CONTACT

Pamela Lim
+65 6870 3212
pamela.lim@thomsonreuters.com